190 related articles for article (PubMed ID: 38673837)
1. Identification of Plasma Lipid Alterations Associated with Melanoma Metastasis.
Szász I; Koroknai V; Várvölgyi T; Pál L; Szűcs S; Pikó P; Emri G; Janka E; Szabó IL; Ádány R; Balázs M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673837
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
3. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
Egberts F; Hitschler WN; Weichenthal M; Hauschild A
Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
[TBL] [Abstract][Full Text] [Related]
4. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.
Hoshimoto S; Shingai T; Morton DL; Kuo C; Faries MB; Chong K; Elashoff D; Wang HJ; Elashoff RM; Hoon DS
J Clin Oncol; 2012 Nov; 30(31):3819-26. PubMed ID: 23008288
[TBL] [Abstract][Full Text] [Related]
5. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
[TBL] [Abstract][Full Text] [Related]
6. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients.
Damude S; Hoekstra HJ; Bastiaannet E; Muller Kobold AC; Kruijff S; Wevers KP
Eur J Surg Oncol; 2016 Apr; 42(4):545-51. PubMed ID: 26831006
[TBL] [Abstract][Full Text] [Related]
7. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U
J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116
[TBL] [Abstract][Full Text] [Related]
8. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma.
Meier F; Will S; Ellwanger U; Schlagenhauff B; Schittek B; Rassner G; Garbe C
Br J Dermatol; 2002 Jul; 147(1):62-70. PubMed ID: 12100186
[TBL] [Abstract][Full Text] [Related]
9. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes.
Porter GA; Abdalla J; Lu M; Smith S; Montgomery D; Grimm E; Ross MI; Mansfield PF; Gershenwald JE; Lee JE
Ann Surg Oncol; 2001 Mar; 8(2):116-22. PubMed ID: 11258775
[TBL] [Abstract][Full Text] [Related]
10. A UHPLC-Mass Spectrometry View of Human Melanocytic Cells Uncovers Potential Lipid Biomarkers of Melanoma.
Perez-Valle A; Abad-García B; Fresnedo O; Barreda-Gómez G; Aspichueta P; Asumendi A; Astigarraga E; Fernández JA; Boyano MD; Ochoa B
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769491
[TBL] [Abstract][Full Text] [Related]
11. Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma.
Peric B; Zagar I; Novakovic S; Zgajnar J; Hocevar M
BMC Cancer; 2011 Aug; 11():328. PubMed ID: 21810220
[TBL] [Abstract][Full Text] [Related]
12. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
13. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
Weide B; Elsässer M; Büttner P; Pflugfelder A; Leiter U; Eigentler TK; Bauer J; Witte M; Meier F; Garbe C
Br J Cancer; 2012 Jul; 107(3):422-8. PubMed ID: 22782342
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
[TBL] [Abstract][Full Text] [Related]
16. Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.
Cubillos-Zapata C; Martínez-García MÁ; Campos-Rodríguez F; Sánchez de la Torre M; Nagore E; Martorell-Calatayud A; Hernández Blasco L; Chiner Vives E; Abad-Capa J; Montserrat JM; Cabriada-Nuño V; Cano-Pumarega I; Corral-Peñafiel J; Diaz-Cambriles T; Mediano O; Somoza-González M; Dalmau-Arias J; Almendros I; Farré R; López-Collazo E; Gozal D; García-Río F;
Eur Respir J; 2019 Feb; 53(2):. PubMed ID: 30487198
[TBL] [Abstract][Full Text] [Related]
17. Lipidomic Profile Revealed the Association of Plasma Lysophosphatidylcholines with Adolescent Obesity.
Wang Y; Jiang CT; Song JY; Song QY; Ma J; Wang HJ
Biomed Res Int; 2019; 2019():1382418. PubMed ID: 31915678
[TBL] [Abstract][Full Text] [Related]
18. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
[TBL] [Abstract][Full Text] [Related]
19. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy.
Weide B; Richter S; Büttner P; Leiter U; Forschner A; Bauer J; Held L; Eigentler TK; Meier F; Garbe C
PLoS One; 2013; 8(11):e81624. PubMed ID: 24312329
[TBL] [Abstract][Full Text] [Related]
20. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
